24.10.18: Not intended for U.S. and UK Media

Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpointThe safety and tolerability observed in the trial were consistent with previously published data on darolutamidemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news